DDInter500 DDInter1628
Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss. Chemically, it consists of 2 heavy and 2 light chains, with each light chain consisting of 215 amino acids and each heavy chain consisting of 448 amino acids with 4 intramolecular disulfides. Denosumab was approved by the FDA approved on June 2010 for the treatment of osteoporosis in postmenopausal women. It further received additional indication approval to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for non-metastatic prostate cancer and women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer in September
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Denosumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dasatinib
Dasatinib {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Denosumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluorouracil
Fluorouracil {u} (Compound) binds {v} (Gene) UMPS
UMPS {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Denosumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dasatinib
Dasatinib {u} (Compound) binds {v} (Gene) MAP3K19
MAP3K19 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Denosumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluorouracil
Fluorouracil {u} (Compound) causes {v} (Side Effect) Anaemia
Anaemia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Denosumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Imatinib
Imatinib {u} (Compound) downregulates {v} (Gene) NPDC1
NPDC1 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Denosumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dasatinib
Dasatinib {u} (Compound) downregulates {v} (Gene) PLK1
PLK1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Denosumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ifosfamide
Ifosfamide {u} (Compound) upregulates {v} (Gene) TATDN2
TATDN2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Denosumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dasatinib
Dasatinib {u} (Compound) downregulates {v} (Gene) URB2
URB2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Denosumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bortezomib
Bortezomib {u} (Compound) upregulates {v} (Gene) MAP3K7
MAP3K7 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Denosumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mitomycin
Mitomycin {u} (Compound) upregulates {v} (Gene) BLCAP
BLCAP {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Fluorouracil and Fluorouracil (Compound) binds UMPS (Gene) and UMPS (Gene) is upregulated by Ruxolitinib (Compound)
Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib (Compound) binds MAP3K19 (Gene) and MAP3K19 (Gene) is bound by Ruxolitinib (Compound)
Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Fluorouracil and Fluorouracil (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Ruxolitinib (Compound)
Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib (Compound) downregulates NPDC1 (Gene) and NPDC1 (Gene) is downregulated by Ruxolitinib (Compound)
Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib (Compound) downregulates PLK1 (Gene) and PLK1 (Gene) is bound by Ruxolitinib (Compound)
Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide (Compound) upregulates TATDN2 (Gene) and TATDN2 (Gene) is upregulated by Ruxolitinib (Compound)
Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib (Compound) downregulates URB2 (Gene) and URB2 (Gene) is upregulated by Ruxolitinib (Compound)
Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib (Compound) upregulates MAP3K7 (Gene) and MAP3K7 (Gene) is bound by Ruxolitinib (Compound)
Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Mitomycin and Mitomycin (Compound) upregulates BLCAP (Gene) and BLCAP (Gene) is downregulated by Ruxolitinib (Compound)